Effectiveness of TNF inhibitor treatment with various methotrexate doses in patients with rheumatoid arthritis: results from clinical practice

Tumour necrosis factor inhibitor (TNFi) treatment in patients with rheumatoid arthritis is more effective when combined with methotrexate (MTX).^{1–3} However, little is known about which MTX dose to use. With great interest, we read the article by Burmester *et al*⁴ on the efficacy and safety of ascending MTX doses with adalimumab. This randomised double-blind study showed comparable results for adalimumab with 10 and 20 mg MTX, in MTX naive patients. Because of the potential side effects, it is often preferred to use MTX doses as low as possible. Therefore, the following questions arise: what happens in daily practice with MTX plus adalimumab, where most patients are not MTX naive when starting TNFi, and are the results the same for etanercept and infliximab?

Data were collected within the Dutch Rheumatoid Arthritis Monitoring (DREAM) registry between 2003 and 2012. Patients starting their first TNFi in combination with MTX were included in the study. Treatment effectiveness was analysed using disease activity score in 28 joints (DAS28) and health assessment questionnaire disability index (HAQ-DI) with linear mixed models for 1 year and long-term drug survival was analysed using Cox regression. Both were corrected for confounders.

Of the 1331 patients in the DREAM cohort starting TNFi plus MTX (551 adalimumab, 610 etanercept, 154 infliximab and 16 others), 430 started with adalimumab and had complete data. MTX should be started at 10–15 mg weekly, which can be increased to 20–25 mg. In daily practice, these four MTX doses are most frequently used starting TNFi and therefore analysed (n=371). The patient characteristics are presented in table 1.

There were no significant differences between the MTX dose groups in DAS28 scores over time, except that the 25 mg MTX group had a worse DAS28 over time than the 15 mg ($\beta=-0.29$; 95% CI=-0.53 to -0.05) and 20 mg ($\beta=-0.54$; 95% CI=-0.80 to -0.28) MTX group (see figure 1). The HAQ-DI over time presented the same trend. There are significant differences

Figure 1 Mean DAS28 over time. DAS28, disease activity score in 28 joints; MTX, methotrexate.

in the 9-year TNFi drug survival between the groups: 25 mg MTX had a significantly worse drug survival than 10, 15 and 20 mg MTX.

Next to adalimumab, etanercept and infliximab are often used in daily practice in combination with 10, 15, 20 or 25 mg MTX (n=396 and n=92, respectively). There were no significant differences in DAS28 over time. However, also in these groups, there were significant differences in drug survival: 25 mg MTX had worse long-term drug survival than 10, 15 and 20 mg MTX.

Focussing on the 10 and 20 mg MTX groups in combination with adalimumab (studied by Burmester *et al*), there are also no significant differences between these groups in daily practice. The same was found for etanercept and infliximab. However, patients who start with adalimumab while on 25 mg MTX, which is common in daily practice, have a significantly worse DAS28 over time and drug survival of the TNFi. This could be a more severe group of patients that can tolerate 25 mg MTX

Table 1 Adalimumab and methotrexate (MTX) data divided into four groups at start of adalimumab (Ada)

	Ada+10 mg MTX (36)	Ada+15 mg MTX (104)	Ada+20 mg MTX (85)	Ada+25 mg MTX (146)	p Value
Mean age (SD), years	56.5 (12.9)	54.7 (11.9)	54.1 (12.4)	50.6 (13.1)	0.015
Female	77.8% (28)	69.2% (72)	64.7% (85)	69.9% (102)	0.556
Median disease duration (IQR)	5.4 (2.6–10.2)	5.1 (1.9–11.2)	5.1 (1.8–13.4)	3.2 (0.9–8.1)	0.027
RF+	80.6% (29)	76.0% (76)	68.3% (56)	63.8% (90)	0.099
Erosive	72.4% (21)	72.6% (61)	66.7% (42)	51.1% (48)	0.001
No. of DMARDs*					0.802
1	58.3% (21)	65.4% (68)	63.5% (54)	58.9% (86)	
2	33.3% (12)	27.9% (29)	30.6% (26)	34.2% (50)	
3	5.6% (2)	6.7% (7)	5.9% (5)	5.5% (8)	
4	2.8% (1)	0.0% (0)	0.0% (0)	1.4% (2)	
DAS28 (SD)	5.15 (1.29)	4.76 (1.29)	4.60 (1.40)	4.55 (1.34)	0.142
HAQ-DI (SD)	1.35 (0.65)	1.22 (0.58)	1.13 (0.62)	1.17 (0.61)	0.410
Oral MTX	62.9% (22)	52.4% (54)	54.1% (46)	51.4% (75)	0.671

The 444 patients received the following MTX doses: 2.5 mg (1), 5 mg (6), 7.5 mg (10), 10 mg (36), 12.5 mg (11), 15 mg (104), 17.5 mg (2), 20 mg (85), 22.5 mg (0), 25 mg (146), 27.5 mg (0), 30 mg (19) and ≥ 35 mg (10).

*Number of DMARDs as comedication next to adalimumab. This includes methotrexate. Other possible DMARDs are sulfasalazine, hydroxychloroquine, leflunomide, aurothiomalate and azathioprine.

DAS28, disease activity score in 28 joints; DMARDs, disease-modifying antirheumatic drugs; HAQ-DI, health assessment questionnaire disability index; RF+, rheumatoid factor positive.

but still have moderate to high disease activity. In conclusion, our data partly support the findings of Burmester *et al* and suggest that patients in the 10 and 15 mg group do not need a higher MTX dose at start with a TNFi treatment.

Sofie H M Manders,¹ Wietske Kievit,² Eddy Adang,² Tim J Jansen,³ Jan N Stolk,⁴ Henk Visser,⁵ Annemarie M Schilder,⁶ Harald E Vonkeman,⁷ Mart A F J van de Laar,⁷ Piet L C M van Riel¹

¹Department of IQ Healthcare, Radboud University Medical Center, Nijmegen, The Netherlands

²Department of Health Evidence, Radboud University Medical Center, Nijmegen, The Netherlands

³Department of Rheumatic diseases, Radboud University Medical Center, Nijmegen, The Netherlands

⁴Department of Rheumatology, Ziekenhuis Gelderse Vallei, Ede, The Netherlands

⁵Department of Rheumatology, Rijnstate, Arnhem, The Netherlands

⁶Department of Rheumatology, Medical Centre Leeuwarden, Leeuwarden, The Netherlands

⁷Department of Rheumatology, Arthritis Centre Twente, University of Twente and Medisch Spectrum Twente, Enschede, The Netherlands

Correspondence to Sofie H M Manders, Department of IQ Healthcare, Radboud University Medical Center, Postbus 9101, Geert Grooteplein Noord 21 (route 114), Nijmegen 6500 HB, The Netherlands; sofie.manders@radboudumc.nl

Contributors All authors are responsible for the work presented in this manuscript. They were involved in at least one of the following: conception and design, acquisition of data, statistical analysis and interpretation of data. All authors were involved in drafting the manuscript and revising the manuscript critically for important intellectual content and have given final approval of the version to be published.

Competing interests None.

Patient consent Obtained.

Ethics approval According to Dutch regulations, the DREAM register does not require ethics approval because no additional data – other than data used for monitoring daily practice – are collected.

Provenance and peer review Not commissioned; internally peer reviewed.

CrossMark

To cite Manders SHM, Kievit W, Adang E, *et al*. *Ann Rheum Dis* 2015;**74**:e24.

Received 17 November 2014

Accepted 18 November 2014

Published Online First 5 December 2014

Ann Rheum Dis 2015;**74**:e24. doi:10.1136/annrheumdis-2014-207005

REFERENCES

- 1 Klareskog L, van der Heijde D, de Jager J, *et al*. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial. *Lancet* 2004;**363**:675–81.
- 2 van der Heijde D, Klareskog L, Rodriguez-Valverde V, *et al*. Comparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trial. *Arthritis Rheum* 2006;**54**:1063–74.
- 3 Breedveld FC, Weisman MH, Kavanaugh AF, *et al*. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. *Arthritis Rheum* 2006;**54**:26–37.
- 4 Burmester GR, Kivitz AJ, Kupper H, *et al*. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trial. *Ann Rheum Dis* 2014.